Last week Endo International (ENDP) shot the lights out. The company beat on revenue and non-GAAP eps, and the good news just keeps on coming on. Friday the FDA determined there was no clinical need to compound vasopressin:

Endo International plc (“Endo”) (NASDAQ: ENDP) today announced that the U.S. Food and Drug Administration (“FDA”) has determined that there is no clinical need to compound vasopressin under Section 503B of the Drug Quality and Security Act. As a result, it will be unlawful for outsourcing facilities to sell compounded vasopressin products unless they manufacture those products using an FDA-approved vasopressin product, rather than bulk vasopressin, or if vasopressin were to be added to the FDA’s drug shortage list. Par Sterile Products, LLC (“Par”), a subsidiary of Endo, is the manufacturer of Vasostrict┬«, the only vasopressin product approved by the FDA. Par and another Endo subsidiary are plaintiffs in a lawsuit against the FDA challenging a previously issued “interim policy” that authorized bulk compounding ofvasopressin in violation of the applicable statute.

“Endo is incredibly pleased that the FDA has correctly concluded that bulk compounding using vasopressin is inappropriate,” said Matthew J. Maletta, Executive Vice President and Chief Legal Officer of Endo. “We appreciate that the FDA is addressing the concerns which prompted our litigation by continuing its efforts to comply with the Drug Quality and Security Act, and we anticipate discussing with the FDA the impact of this decision on our pending litigation in the near future.”

This is fabulous news for Endo. Will the FDA decision be the catalyst that sends the stock higher? Read more:

print

LEAVE A REPLY

Please enter your comment!
Please enter your name here